How Smart Drugs Work in Bladder Cancer Treatment
The primary criterion in selecting targeted therapies is ensuring that the target antigen is highly expressed on malignant cells while remaining minimally expressed or absent on normal, healthy tissues. In the context of bladder cancer treatment with Enfortumab Vedotin, this requires high expression of Nectin-4 on the cancer cell surface and low expression in normal tissue cells. The Antibody-Drug Conjugate (ADC) must bind rapidly to the Nectin-4 antigen and undergo swift internalization into the cell, accompanied by the necessary disruption of intercellular junctions surrounding the cancer cells.
What is Nectin-4?
Nectin-4 is a cell-surface adhesion protein frequently overexpressed by malignant cells in urothelial carcinomas of the bladder and upper urinary tract (including the ureters and renal pelvis). The epithelial lining throughout the urinary bladder, renal collecting systems, and ureters shares structural continuity and is referred to as the urothelium or uroepithelial membrane. Urothelial cancers originating from this lining demonstrate a very high prevalence of Nectin-4 expression. Clinical studies indicate that Nectin-4 expression rates exceed 80% in urothelial cancers of the bladder, ureter, and renal pelvis.
Literature notes that Nectin-4 expression is even higher in specific histological variants such as micropapillary urothelial carcinoma, whereas it tends to be lower in sarcomatoid variants. Enfortumab Vedotin, an ADC, binds directly to Nectin-4 to facilitate targeted cellular entry.
The 'Trojan Horse' in Bladder Cancer: What is Enfortumab Vedotin (EV)?
Enfortumab Vedotin (EV) is an Antibody-Drug Conjugate (ADC) composed of a fully human monoclonal antibody targeted against Nectin-4, covalently linked via a protease-cleavable linker to a potent cytotoxic agent, Monomethyl Auristatin E (MMAE). As one of the breakthrough antibody-drug conjugates introduced into bladder cancer treatment, it specifically homes in on Nectin-4 expressed on the cancer cell surface.
|
Mechanism of Action (The Trojan Horse Pathway): |
Clinical Application & Combination Regimens
In clinical practice, Enfortumab Vedotin is administered in advanced-stage bladder cancer cases as a combination therapy alongside immunotherapy. Specifically, the regimen pairs Enfortumab Vedotin (administered at 12.5 mg/kg on Days 1 and 8 of a 21-day cycle) with Pembrolizumab (200 mg).
While traditionally reserved for patients who are ineligible for Cisplatin-Gemcitabine chemotherapy or have progressed following platinum-based therapies, this breakthrough combination has now emerged as a first-line standard of care option in advanced urothelial carcinoma.
Prof. Dr. Tibet Erdogru
Urology
